A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Healthy Adults
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Influenza virus vaccine trivalent Novavax (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cadila Pharmaceuticals
- 06 Feb 2013 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
- 13 Nov 2012 New trial record